Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaThomas Powles, Noah M. Hahn, Ashok Gupta et al.|JAMA Oncology|2017Cited by 846
Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at RecurrenceAndrea Marie Ibrahim, Michael Ong, Melanie Le May et al.|Annals of Surgical Oncology|2020Cited by 18
Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic ReviewKerianne Boulva, Carolyn Nessim, Sameer Apte et al.|Cancers|2021Cited by 13
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, M. Neil Reaume, Kim Koczka et al.|Medical Oncology|2019Cited by 7
Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlationBrian A. Keller, John C. Bell, Brian J. Laight et al.|Journal of Cancer Research and Clinical Oncology|2021Cited by 4